Provention Bio, Inc.
PRVB · NASDAQ
12/31/2022 | 9/30/2022 | 6/30/2022 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.18 | 0.13 | -0.07 | 0.36 |
| FCF Yield | -1.06% | -6.46% | -11.07% | -3.24% |
| EV / EBITDA | -20.24 | -10.46 | -6.79 | -13.47 |
| Quality | ||||
| ROIC | -23.04% | -16.96% | -37.48% | -23.07% |
| Gross Margin | 95.26% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.24 | 0.84 | 0.96 | 0.68 |
| Growth | ||||
| Revenue 3-Year CAGR | 2,344,887.05% | 1,409,191.93% | 1,395,977.46% | 1,254,549.35% |
| Free Cash Flow Growth | 65.45% | 15.70% | -90.70% | 36.04% |
| Safety | ||||
| Net Debt / EBITDA | 0.53 | 2.78 | 1.93 | 2.57 |
| Interest Coverage | -51.37 | -114.03 | -204.34 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.42 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -960.76 | 0.00 | 0.00 | 0.00 |